Managing large cutaneous squamous cell carcinoma with programmed cell death protein 1 inhibitor monotherapy: Real-world experience at a single center

oleh: Sach Thakker, BS, Mairead R. Baker, MD, Jafar Al-Mondhiry, MA, MD, Sekwon Jang, MD, Jennifer A. DeSimone, MD

Format: Article
Diterbitkan: Elsevier 2024-09-01

Deskripsi

Subjek

cemiplimab; cutaneous oncology; immunotherapy; PD-1 inhibitor; pembrolizumab; squamous cell carcinoma